Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) have earned an average rating of “Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $9.75.

ACHN has been the topic of several recent research reports. Maxim Group reduced their target price on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. TheStreet lowered shares of Achillion Pharmaceuticals from a “c-” rating to a “d” rating in a report on Wednesday, March 22nd. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Finally, Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $6.00 in a report on Thursday, May 18th.

COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of “Buy” from Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/20/achillion-pharmaceuticals-inc-achn-receives-consensus-rating-of-buy-from-brokerages-2.html.

Shares of Achillion Pharmaceuticals (ACHN) opened at 4.37 on Tuesday. The firm’s market capitalization is $597.48 million. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49. The stock has a 50 day moving average of $4.12 and a 200-day moving average of $4.07.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. During the same quarter in the prior year, the business posted ($0.13) EPS. Equities analysts expect that Achillion Pharmaceuticals will post ($0.64) earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI raised its stake in shares of Achillion Pharmaceuticals by 1.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 50,102 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 699 shares during the period. Pacad Investment Ltd. raised its stake in shares of Achillion Pharmaceuticals by 2.4% in the fourth quarter. Pacad Investment Ltd. now owns 37,800 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 900 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,600 shares during the period. Creative Planning raised its stake in shares of Achillion Pharmaceuticals by 2.0% in the first quarter. Creative Planning now owns 155,576 shares of the biopharmaceutical company’s stock worth $655,000 after buying an additional 3,000 shares during the period. Finally, Deschutes Portfolio Strategy LLC raised its stake in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 3,000 shares during the period. 71.26% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.